Výsledky vyhledávání

Akademický článek

Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial

Autor: Stephen B Hanauer, William J Sandborn, Christian Dallaire, André Archambault, Bruce Yacyshyn, Chyon Yeh, Nancy Smith-Hall

Publikováno v: Canadian Journal of Gastroenterology, Vol 21, Iss 12, Pp 827-834 (2007)

BACKGROUND: Delayed-release oral mesalamine 2.4 g/day to 4.8 g/day has been shown to be effective in treating mildly to moderately active ulcerative colitis (UC), but it is unknown whether an initial dose of 4.8 g/day is more effective than 2.4 g/day

Externí odkaz: https://doaj.org/article/ad3278ef9a5649a2863d0e867761ade8

Zobrazit plný text záznamu

Two-year target vessel-related outcomes following use of off-the-shelf branched endografts for the treatment of thoracoabdominal aortic aneurysms

Autor: Nikolaos Tsilimparis, Michel Bosiers, Timothy Resch, Giovanni Torsello, Martin Austermann, Fiona Rohlffs, Brandon Coates, Chyon Yeh, Tilo Kölbel

Publikováno v: Journal of Vascular Surgery.

OBJECTIVES To assess clinical outcomes and target vessel patency through 2 years following thoracoabdominal aortic aneurysms (TAAA) repair with the off-the-shelf Zenith® t-Branch® Thoracoabdominal Endovascular Graft (William Cook Europe, Bjaeversko

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417a8f82d29aff2085dd3417a52375cc
https://doi.org/10.1016/j.jvs.2023.03.498

Zobrazit plný text záznamu

Updated outcomes from the TRANSFIX study to evaluate endovascular repair of blunt thoracic aortic injuries with the Zenith Alpha thoracic device

Autor: Karen Woo, Joseph S. Giglia, Amit J. Dwivedi, Chyon Yeh, Transfix Study Investigators, Benjamin W. Starnes

Publikováno v: Journal of vascular surgery. 71(6)

Objective The purpose of this study was to report the updated results of a prospective, multicenter, nonrandomized, single-arm investigational device exemption study conducted at 17 sites in the United States to assess safety and effectiveness of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84caa21c84e81062f64dbe11416f6fab
https://pubmed.ncbi.nlm.nih.gov/32446505

Zobrazit plný text záznamu

Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial

Autor: A. Archambault, Nancy Smith-Hall, William J. Sandborn, Chyon Yeh, Stephen B. Hanauer, Bruce Rudolf Yacyshyn, Christian Dallaire

Publikováno v: Canadian Journal of Gastroenterology, Vol 21, Iss 12, Pp 827-834 (2007)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e70d5908924baf46f0b486983676f9d
https://doi.org/10.1155/2007/862917

Zobrazit plný text záznamu

Endovascular repair for blunt thoracic aortic injury using the Zenith Alpha low-profile device

Publikováno v: Journal of Vascular Surgery. 62:1495-1503.e1

Objective The objective of this study was to report 30-day results from a prospective, nonrandomized, multicenter trial that evaluated the safety and effectiveness of the Zenith Alpha thoracic endovascular graft (Cook Medical, Bloomington, Ind) for t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88969d2ef2ad86c80b5d05eed3d65867
https://doi.org/10.1016/j.jvs.2015.07.098

Zobrazit plný text záznamu

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

Autor: Jaroslaw Regula, Chyon Yeh, Elena Belousova, Milan Lukas, Piotr Krzeski, William J. Sandborn, Stephen B. Hanauer, Brian G. Feagan, Christi A. Messer, Bruce R. Yacyshyn, Njegica Jojic

Publikováno v: Gastroenterology. 137(6)

Background and Aims It is not clear what induction dose of mesalamine is optimal for treating patients with mildly and moderately active ulcerative colitis (UC). This study was conducted to determine the efficacy and safety of mesalamine 4.8 g/day co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9544ae550e3aa243d335bb0bd0d6c48
https://pubmed.ncbi.nlm.nih.gov/19879213

Zobrazit plný text záznamu

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

Autor: Nancy Smith-Hall, William J. Sandborn, Asher Kornbluth, Scott D. Woogen, Michael Safdi, Funmilay Ajayi, Gino Regalli, Seymour Katz, Chyon Yeh, Stephen B. Hanauer

Publikováno v: The American journal of gastroenterology. 100(11)

Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4.8 g/day provided additional efficacy benefit compared to 1.6 g/day in patients with mildly to moderately active ulcerative colitis. Additionally, Asacol dosed at 2.4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d44598de1d7ae8ba18418bf82b5f24
https://pubmed.ncbi.nlm.nih.gov/16279903

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání